Determinants of Intraocular Pressure and Time to Blindness for Glaucoma Patients at Felege Hiwot Referral Hospital, Bahir Bar, Ethiopia: A Comparison of Separate and Joint Models

Mitiku Wale Muluneh[1] [iD] and Awoke Seyoum Tegegne[2]

[1]Department of Statistics, Faculty of Natural and Computational Science, Debre Tabor University, Debre Tabor, Ethiopia. [2]Department of Statistics, College of Science, Bahir Dar University, Bahir Dar, Ethiopia.

ABSTRACT

BACKGROUND: Due to the substantial increase in the number of glaucoma cases within the next several decades, glaucoma is a significant public health issue. The main objective of this study was to investigate the determinant factors of intraocular pressure and time to blindness of glaucoma patients under treatment at Felege Hiwot Referral Hospital, Bahir Dar, Ethiopia.

METHODS: A retrospective study design was conducted on 328 randomly selected glaucoma patients using simple random sampling based on the identification number of patients in an ophthalmology clinic at the hospital under the follow-up period from January 2014 to December 2018. A linear mixed effects model for intraocular pressure data, a semi-parametric survival model for the time-to-blindness data and joint modeling of the 2 responses were used for data analysis. However, the primary outcome was survival time of glaucoma patients.

RESULTS: The comparison of joint and separate models revealed that joint model was more adequate and efficient inferences because of its smaller standard errors in parameter estimations. This was also approved using AIC, BIC, and based on a significant likelihood ratio test as well. The estimated association parameter (α) in the joint model was .0160 and statistically significant (*P*-value = .0349). This indicated that there was strong evidence for positive association between the effects of intraocular pressure and the risk of blindness. The result indicated that the higher value of intraocular pressure was associated with the higher risk of blindness. Age, hypertension, type of medication, cup-disk ratio significantly affects both average intraocular pressure and survival time of glaucoma patients (*P*-value < .05).

CONCLUSION: The predictors; age, hypertension, type of medication, and cup-disk ratio were significantly associated with the 2 responses of glaucoma patients. Health professionals give more attention to patients who have blood pressure and cup-disk ratio greater than 0.7 during the follow-up time to reduce the risk of blindness of glaucoma patients.

KEYWORDS: Intraocular pressure, time to blindness, linear mixed model, joint model, Cox proportional hazard model

Background

Glaucoma is a leading cause of irreversible blindness worldwide and associated with characteristic damage to the optic nerve and patterns of visual field loss due to retinal ganglion cell degeneration.[1] Glaucoma encompasses a group of ophthalmic diseases that are believed to share the common pathophysiology of elevated intraocular pressure and causes irreversible visual loss.[2]

IOP is the fluid pressure inside the eye and eye care professionals' uses tonometer to determine this. Most tonometers are calibrated to measure pressure in millimeters of mercury (mmHg).[3] Ocular hypertension refers to a situation in which the pressure inside the eye is higher than 21 mmHg. Normal eye pressure ranges from 10 to 21 mmHg.[4]

Due to the substantial increase in the projected number of glaucoma cases within the next several decades, glaucoma is a significant public health issue. The visual outcome is the major

concern of glaucoma patients.[5] At diagnosis, 34% of glaucoma patients are worried about the probability of becoming blind in the future; even if this percentage decreases to 11% at follow-up times.[6] Some studies have been conducted related to glaucoma to determine factors affecting the survival time and longitudinal outcomes separately.[7] A study conducted to determine factors that affect the longitudinal change of IOP using linear mixed model.[8] However, the linear mixed model of longitudinal data and the Cox proportional hazards model for time-to-event data, conducted separately do not consider dependencies or interrelationships between these 2 different data types of responses.[9] Hence, an alternative approach of joint modeling of these 2 types of responses was proposed by several researchers.[9-13]

Joint models of longitudinal and survival data can incorporate all information simultaneously and provide valid and efficient inferences for the given data.[14] There is scarcity of

research conducted previously about joint models of longitudinal variation of IOP and time to blindness of glaucoma patients in the study area. Therefore, this study was aimed to investigate joint determinants of change of IOP and time to blindness of glaucoma patients under treatment at Felege Hiwot Referral Hospital, North-West Ethiopia. The result obtained in this investigation helps glaucoma patients and health professionals as well to reduce the number of people being blind because of glaucoma and related diseases.

Materials and Methods

Description of study area and design

This study was conducted at Felege Hiwot Referral Hospital, Bahir Dar, North West Ethiopia. The area is located 563 km far from Addis Ababa, capital city of the country. This hospital also serves as a referral hospital for the people who are referred from different districts. A retrospective study design was carried out to retrieve relevant information from the medical records of glaucoma patients to address the objective of current investigation.

Source of population and data

The glaucoma patients were the source of population for this study. The data was collected from the medical chart of glaucoma patients in the ophthalmology clinic at the hospital whose follow-ups were January 2014 to December 2018. Both the longitudinal and survival data were extracted from the patient's chart which contains socio-demographic and clinical information of all glaucoma patients under follow-ups. Hence, the data for current investigation was secondary.

Data collection procedures

Ophthalmologic clinic staff and clinical nurses participated in collecting secondary data from cards of patients and a public health expert was assigned as a supervisor and orientation was given for data collectors about the variables included in the investigation.

Quality of data measurement

The data collection tool was pre-tested before the actual data collection to maintain data quality. The completeness and consistency of questions related to secondary data were checked and pre-tested on 45 sample data and proper amendments were included after getting feedback from the pilot test. Data cleaning was conducted on a daily basis and timely feedback was communicated to the data collectors.

Sample size and sampling procedures

Taking Bahir Dar referral hospital, the division of ophthalmology in eye treatment, the target population for this study was recorded eye patients confirmed at Bahir Dar referral hospital. At the time when data was collected, there were more eye patients which were recorded in the hospital during January 2014 to December 2018. For each patient, blindness from glaucoma of at least 1 eye occurring during the time of observation was considered as an event. A simple random sampling method was employed for selecting a representative sample in which each of the patients had an equal chance of being selected to be part of the study. Using a single proportion formula by taking blindness prevalence 0.41 as the estimate of population proportion (P) from the previous study in Ethiopia, Menelik II Hospital,[15] 95% confidence interval, 5% margin of error, and adding 10% considering the possible missing records to compensate. Finally, the total sample size was 328.

Variables in the Study

Response variables

The 2 response variables were measures of IOP in mmHg and the survival time of glaucoma patients. The IOP was measured in millimeters of mercury (mmHg) which was measured every 6 months irrespective of patient visits to the ophthalmology clinic of the hospital and a patient with full follow ups had 11 visits including baseline. The survival time of glaucoma patients is the length of time from follow-up start date until the date of blindness (or censor). Glaucoma patients who stayed alive during study time, lost follow-up, or died by other causes were considered as censored. Therefore, survival time of glaucoma is assumed to be the outcome of interest in the analysis. The survival response, survival time in months, is created by subtracting the date of the entry from the date of the last visit.

Independent variables

The independent variables for this study were gender (Female = 0 and Male = 1), Place of residence (Rural = 0 and Urban = 1), age in years, hypertension (No = 0 and Yes = 1), diabetic disease (No = 0 and Yes = 1), type of medication (Timolol = 0, Timolol with Pilocarpine = 1, Timolol with Diamox = 2, and Timolol with Diamox with Pilocarpine = 3), duration of treatment (Short = 0, Medium = 1, and long = 2), stage of glaucoma (Early = 0, Moderate = 1, and Advanced = 2), cup-disk ratio (≤ 0.7 = 0 and >0.7 = 1).

Data processing and analysis

In this study, R 3.5.3 version software was considered for data analysis. Statistical decision was made at 5% of level of significance.

Statistical Models

Linear mixed effect model

A linear mixed model is a parametric linear model for longitudinal or repeated measures data that quantifies the

relationships between a continuous dependent variable and various predictor variables. It extends from the classical linear regression model that takes into account both fixed effect and random effect. The random effect contains subject specific effects and the fixed effect contains the set of predictors that are fixed across the subjects or the same for all subjects. The fixed effect parameters describe the relationships of the predictors to the dependent variable for an entire population and random effects are specific to subjects within a population. Consequently, random effects are directly used in modeling the random variation in the dependent variable.[16] The random effects are not only determining the correlation structure between observations on the same subject but also take account of heterogeneity among subjects, due to unobserved characteristics.

The general linear mixed effects model defined as

$$y_i = X_i \beta + Z_i b_i + \varepsilon_i$$

Where,

- ✓ y_i is the $(n_i \times 1)$ vector of repeated measurements for i^{th} subject
- ✓ β is a $p \times 1$ vector of the fixed effects parameter
- ✓ X_i is a $n_i \times p$ known design matrix corresponding to fixed effects β
- ✓ b_i is a $q \times 1$ vector of random effects parameters
- ✓ Z_i is a $n_i \times q$ known design matrix corresponding to random effects b_i
- ✓ ε_i is the $(n_i \times 1)$ vector of the error terms.

The corresponding assumptions for model are $b_i \sim N(0, G)$ and $\varepsilon_i \sim N(0, R_i)$; where, G and R_i are the variance-covariance matrix for b_i and ε_i respectively and R_i represents the diagonal matrix of $\sigma^2 I_{n_i}$ with an $n_i \times n_i$ identity matrix I_{n_i}. The random effects are assumed to be independent of the error terms ε_i, that means $cov(b_i, \varepsilon_i) = 0$. The assumption $var(\varepsilon_i) = \sigma_\varepsilon^2 I$ can be relaxed by allowing to model non-constant variance or special within group correlation structures.

Survival model

Survival analysis is a collection of statistical procedures for data analysis for which the outcome a variable of interest is time until an event occurs. The term survival analysis applies to techniques in which the data being analyzed is the time the process takes for a certain event of interest to occur. It is most important when there is censoring data as opposed to the use of different statistical methods. It involves the modeling and analysis of data that has a principal end point the time until an event occurs (time-to-event data). By time, it is to mean years, months, weeks, or days from the beginning of follow-up of an individual until an event occurs. To summarize survival data there are 2 functions of central interest namely the survivor function and the hazard function.

Survivor function (S(t))

Let "T" be a random variable associated with the survival times (t), survival times (t) be the realization of the random variable T and $f(t)$ be the underlying probability density function of the survival time t. Then the cumulative distribution function $F(t)$, which represents the probability that a subject selected at random will have a survival time less than some stated value t. The distribution function of T is given by:

$$F(t) = P(T \le t) = \int_0^t f(u) du, t \ge 0$$

where, $F(t)$ = the probability that a patient gets blind before time t.

The survivor function ($S(t)$) is defined to be the probability that the survival time of a randomly the selected subject survives beyond some specified time t and so.

$$S(t) = P(T > t) = 1 - F(t) = \int_t^\infty f(u) du, t \ge 0$$

Hazard function (h(t))

The hazard function is widely used to express the risk of hazard of death at time t. It is obtained from the probability that an individual dies at time t, given that the individual has survived up to time t. It is also known as the conditional failure rate in reliability, the force of mortality in demography, the intensity function in stochastic process, the age specific failure rate in epidemiology, the inverse of the Mill's ratio in economics or simply the hazard rate (Hosmer and Lemeshow, 1999). It gives the instantaneous potential per unit time for the event to occur, given that the individual has survived up to time t. The hazard function ($h(t)$) is given as:

$$h(t) = \lim_{\Delta t \to 0} \frac{P\left[(t \le T < t + \Delta t)/T \ge t\right]}{\Delta t}$$

By applying the theory of conditional probability and the relationship in equation, the hazard function can be expressed in terms of the underlying probability density function and the survival function as follows.

$$h(t) = \frac{f(t)}{S(t)} = \frac{-d}{dt} \ln S(t)$$

A related quantity is the cumulative hazard function $H(t)$ which is defined by:

$$H(t) = \int_0^t h(u) du = -\ln s(t)$$

Thus, $S(t) = exp(-H(t))$; consequently,

$$f(t) = h(t) exp(-H(t))$$

Kaplan-Meier (KM)

The Kaplan-Meier (KM) estimator, or Product Limit estimator, is the standard non-parametric estimator of the survival function $S(t)$. It incorporates information from all of the observations available, both censored and uncensored, by considering any point in time as a series of steps defined by the observed survival and censored times. When there is no censoring, the estimator is simply the sample proportion of observations with event times greater than t. The technique becomes a little more complicated, but still manageable when censored times are included.

Suppose $t_1, t_2, \ldots, t_n$ be the observed survival times for n subject and consider that m subjects experienced the event, $t_{(1)} \leq t_{(2)} \leq \ldots \leq t_{(m)}$, $m \leq n$ being the m distinct ordered survival times. Then the KM estimator of the survivor function at time t is given by

$$\hat{S}_{KM}(t) = \begin{cases} 1 & if\ t < t_{(1)} \\ \prod_{t(i) \leq t} \left(\dfrac{n_i - d_i}{n_i} \right) & if\ t \geq t_{(1)} \end{cases}$$

Where,
$d_i =$ The number of glaucoma patients who experience the event (blind) at time t_i
$n_i =$ The number of patients who have not yet experienced the event (blind) or the total number of individuals at risk before at time t_i.

Log-rank test

The log-rank test, sometimes called the Cox-Mantel test, is the most well-known and widely used test statistic. This test statistic is based on weights equal to 1, that is, $W_i = 1. i = 1, 2, \ldots, m$.

The log rank test was used to compare 2 or more independent survival curves and useful for non-overlapping survival curves. The log rank test statistic for comparing 2 groups is given by:

$$Q_{LR} = \frac{\left[\sum_{i=1}^{m} \left(d_{1i} - \hat{e}_{1i} \right) \right]^2}{\sum_{i=1}^{m} V_{1i}}$$

Cox proportional hazard model

One of the most popular types of regression models used in survival analysis is the Cox proportional hazard model. Although the model is based on the assumption of proportional

hazards, no particular form of probability distribution is assumed for the survival times. The model is therefore referred to as a semi-parametric model. The Cox model, a regression method for survival data, provides an estimate of the hazard ratio which is always non-negative and its confidence interval. The hazard ratio is an estimate of the ratio of the hazard rate based on comparison of event rates. The hazard function $h(t, w, \gamma)$ is related to the covariates as a product of a baseline hazard $h_0(t)$ and a function of covariates $r(w, \gamma)$.

Cox (1972) was the first to propose $r(w, \gamma) = \exp(w^T \gamma)$ and the baseline hazard is left unspecified as a nuisance parameter in the model. Therefore, the Cox proportional hazard function is given as

$$h(t, w, \gamma) = h_0(t) exp(w^T \gamma)$$

Where, $h_0(t) =$ the baseline hazard function that characterizes how the hazard function changes as a function of survival time. $h(t, w, \gamma) =$ the hazard function at time t with covariates $w = (w_1, w_2, \ldots, w_p)$ and a column vector of p regression parameters $\gamma = (\gamma_1, \gamma_2, \ldots, \gamma_p)$.
$Exp(X'\beta) =$ characterizes how the hazard function changes as a function of subject covariates.
$t =$ the failure times.

The ratio of the hazard functions for 2 subjects with covariate values denoted $w_1\ and\ w_2$ is given by

$$HR(t, w_1, w_2) = \frac{h(t, w_2, \gamma)}{h(t, w_1, \gamma)} = \frac{h_0(t) r(w_2, \gamma)}{h_0(t) r(w_1, \gamma)}$$
$$= \frac{r(w_2, \gamma)}{r(w_1, \gamma)} = e^{\gamma(w_2 - w_1)},$$

Therefore, the hazard ratio (HR) depends only on the function $r(w, \gamma)$. This model is referred to as the Cox model, the Cox proportional hazards model or simply the proportional hazards model. The term proportional hazards refer to the fact that the hazard functions are multiplicatively related (ie, their ratio is constant over survival time).

Joint modeling for longitudinal and survival data

In clinical trials, it is common to see repeated measures with time to event which generate both longitudinal data and survival data. One of the natural strategies considering in the joint analysis of longitudinal and survival data is to incorporate the longitudinal measures directly into the Cox PH model as time-varying covariates and then proceed with the Cox proportional hazard model analysis.[17] The intuitive idea behind these models is to couple the survival model, which is of primary interest, with a suitable model for the repeated measurements of the endogenous covariates that will account for its special features. In this situation, a linear mixed effect sub-model was used to model time-varying covariate to address measurement errors (to describe the evolution of the marker in time for each

patient) and a Cox proportional hazard sub-model to model the survival data.

Therefore, to examine the impact of the longitudinal outcome to the hazard for an event, an estimate of $m_i(t)$ was needed in order to reconstruct the complete true history $m_i(t)$ to each subject. The joint model of change of IOP and time to blindness was described by a linear mixed effects model as: $y_{ij} = \left\{ y_i(t_{ij}), j = 1, 2, \ldots, n_i \right\}$ of ith subject at time $t_{i1}, t_{i2}, \ldots, t_{in_i}$ is modeled as.[18]

$$y_i(t) = x_i'(t)\beta + z_i'(t)b_i + \varepsilon_i(t)$$

$$= m_i(t) + \varepsilon_i(t), m_i(t) = x_i'(t)\beta + z_i'(t)b_i$$

$$b_i \sim N(0, G), \varepsilon_i(t) \sim N(0, \sigma^2)$$

where $x_i(t)$ and $z_i(t)$ are the design vectors for fixed effects β, and for the random effectes b_i respectively, $\varepsilon_i(t)$ are the error terms.

Results

The patient characteristics of current investigation indicates that among the participants, 108 (32.9%) were females, 146 (45.5%) were from rural area, 98 (29.9%) had hypertension, and 48 (14.6%) were diabetic patients, 65(19.8%), 82(25.0%), 111(33.8%), and 70(21.3%) patients were treated by Timolol, Timolol with Pilocarpine, Timolol with Diamox, and Timolol with Pilocarpine with Diamox respectively. One hundred thirty-five (41.2%), 106 (32.3%), and 87 (26.5%) patients had short treatment duration, medium treatment duration and long treatment duration respectively. One hundred twenty-one (36.9%), 52 (15.9%), and 155(47.3%) had early-stage glaucoma, moderate stage glaucoma, and advanced stage glaucoma respectively. Similarly, 173 (52.7%) of the patients had a maximum of 0.7 cup-disk ratio and the rest 155 (47.3%) of the patients had at least 0.7 cup-disk ratio. Among the total of 328 glaucoma patients, 106 (32.3%) were blind whereas 222 (67.7%) were censored. Among the blind patients, 28 (8.5%) female patients were blind, 74 (22.6%) hypertensive patients were blind, 33 (10.1%) diabetic patients were blind. Similarly, 47 (14.3%) patients who had short term treatment were blind, 45 (13.7%) patients who had medium term treatment were blind, and only 14(4.3%) patients who had long treatment duration were blind. The mean IOP of females and males were 28.29 and 29.92 respectively. The mean age of glaucoma patients at enrollment of ophthalmology clinic was 55.9 years with a standard deviation of 17.4, the youngest patient was 6 years old and the eldest was 89 years old (Table 1).

The Kaplan-Meier estimate shows that the median survival time of glaucoma patient was 59 months (Table 2).

The Kaplan-Meier survival curves for each study variable provide an initial insight for the shape of survival function. The Kaplan-Meier survival curves to see whether there is a difference in time to blindness between different categories of the covariates. The overall survival curve of glaucoma patients was decreased when the time in months increased (Figure 1).

The variables hypertension, diabetic disease, type of medication, duration of treatment, stage of glaucoma, and cup-disk ratio were statistically significant differences between the survival experience (time to blindness) of different groups of glaucoma patients. However, gender and residence there were no survival experience differences between the groups at 5% of level of significance (Table 3).

The model with the smallest AIC and BIC value of covariance structure. Therefore, first order autoregressive (AR (1)) covariance structure was selected due to the smallest AIC and BIC compared to the remaining covariance structures (Table 4).

The random intercept and slope model allow the intercept and coefficient to vary randomly among individuals. That means, individual IOP of glaucoma patients vary from visit to visit randomly. Therefore, the random intercept and slope model more parsimonious model for the linear mixed effects model on the basis of its lower values of AIC and BIC (Table 5).

Univariable analysis for linear mixed model

A univariable analysis was performed in order to see the effect of each covariate on intraocular pressure by using purposeful variable selection in linear mixed effect model analysis and to select variables to be included in the multivariable analysis. Based on univariable analysis all predictors were a candidate variable for multivariable analysis of linear mixed models at 25% level of significance.

Multivariable analysis for linear mixed model

Multivariable analysis of linear mixed model was done by considering all significant covariates at univariable analysis. The result showed that the predictors, age, place of residence, hypertension, type of medication, cup-disk ratio, and visits were significantly associated with the average IOP at 5% of level of significance. Under the random effects result, the estimated subject-specific variability was statistically significant at 5% level of significance (Table 6).

Univariable analysis for Cox proportional hazard model

The variables which were significant at the *P*-values less than .25 at univariable analysis were included in the multivariable analysis. The result of the univariable analysis indicated that all predictors were statistically significant at 25% level of significance for Cox proportional hazard model and taken as candidate variables for multivariable analysis.

Multivariable analysis for Cox proportional hazard model

The multivariable analysis of Cox proportional hazard model indicates that the predictors; age, hypertension, diabetic disease, duration of treatment, and cup-disk ratio were significantly

Table 1. Characteristics of categorical variables of glaucoma patients.

VARIABLES	CATEGORIES	NO. PATIENT (%)	STATUS OF PATIENTS		MEAN IOP
			BLIND	NOT BLIND	
Gender	Female	108 (32.9)	28 (8.5)	80 (24.4)	28.29
	Male	220 (67.1)	78 (23.8)	142 (43.3)	29.92
Place of residence	Rural	146 (44.5)	61 (18.6)	85 (25.9)	30.90
	Urban	182 (55.5)	45 (13.7)	137 (41.8)	28.05
Hypertension	No	230 (70.1)	32 (9.8)	198 (60.4)	27.09
	Yes	98 (29.9)	74 (22.6)	24 (7.3)	35.16
Diabetic disease	No	280 (85.4)	73 (22.3)	207 (63.1)	28.65
	Yes	48 (14.6)	33 (10.1)	15 (4.6)	33.71
Type of medication	Timolol	65 (19.8)	23 (7.0)	42 (12.8)	29.98
	Timolol and Pilocarpine	82 (25.0)	22 (6.7)	60 (18.3)	27.67
	Timolol and Diamox	111 (33.8)	35 (10.7)	76 (23.2)	29.66
	Timolol, Pilocarpine, and Diamox	70 (21.3)	26 (7.9)	44 (13.4)	30.60
Duration of treatment	Short	135 (41.2)	47 (14.3)	88 (26.8)	30.08
	Medium	106 (32.3)	45 (13.7)	61 (18.6)	30.81
	Long	87 (26.3)	14 (4.3)	73 (22.3)	27.51
Stage of glaucoma	Early	121 (36.9)	13 (4.0)	108 (32.9)	26.95
	Moderate	52 (15.9)	11 (3.4)	41 (12.5)	28.86
	Advanced	155 (47.3)	82 (25.0)	67 (20.4)	31.84
Cup-disk ratio	″ 0.7	173 (52.7)	14 (4.3)	159 (48.5)	26.84
	>0.7	153 (47.3)	92 (28.0)	61 (18.6)	32.59
	Minimum	Maximum	Mean	SD	
Age in years	6	89	55.9	17.4	

Table 2. The Kaplan-Meier (product-limit) survival estimates.

TIME	NO. AT RISK	NO. BLIND	NO. CENSORED	SURVIVAL	SE	95% CI	
						LOWER	UPPER
6	328	12	15	0.963	0.0104	0.943	0.984
12	301	10	16	0.931	0.0141	0.904	0.960
18	275	9	17	0.901	0.0169	0.868	0.935
24	249	8	21	0.872	0.0192	0.835	0.910
30	220	9	19	0.836	0.0218	0.795	0.880
36	192	11	20	0.788	0.0249	0.741	0.839
42	161	14	24	0.720	0.0287	0.666	0.778
46	123	1	0	0.714	0.0290	0.659	0.773
47	122	1	0	0.708	0.0294	0.653	0.768
48	121	18	19	0.603	0.0339	0.540	0.673
54	84	12	65	0.517	0.0371	0.449	0.595
59	7	1	0	0.445	0.0754	0.317	0.618
60	6	0	6	0.445	0.0754	0.317	0.618

## Overall survival curve of glaucoma patients

Figure 1. The overall estimate of Kaplan-Meier survival curve of glaucoma patients.

Table 3. Results of the log-rank test for each categorical variable of glaucoma patients.

COVARIATES	DF	CHI-SQUARE	P-VALUE
Gender	1	1.8	.2000
Residence	1	3.5	.0600
Hypertension	1	110	<.0001*
Diabetic disease	1	24.4	<.0001*
Type of medication	3	117.5	<.0001*
Duration of treatment	2	155	<.0001*
Stage of glaucoma	2	45.4	<.0001*
Cup-disk ratio	1	101	<.0001*

*Shows significant at .05 level of significance.

Table 4. Comparison of covariance structure for linear mixed-effects model.

COVARIANCE STRUCTURE	AIC	BIC	LOG LIKELIHOOD
CS	15528.87	15620.52	−7748.434
AR (1)	**15526.72**	**15618.37**	**−7757.362**
UN	15526.87	15619.79	−7748.434

Bold shows smaller AIC and BIC.

associated with time to blindness of glaucoma patients at 5% of level of significance (Table 7).

In the longitudinal sub model, the estimated coefficient of fixed effect intercept was 25.1515, indicates that the average IOP of the patients was 25.1515 mmHg at baseline time by excluding all covariates in the model (P-value < .0001). For a

Table 5. Selection of random effects to be included in the LMM.

MODELS FOR RANDOM EFFECT	AIC	BIC	LOG LIKELIHOOD
Random intercept	15531.24	15621.43	−7751.621
Random slope	15657.57	15737.76	−7814.782
Random intercept and slope	**15526.72**	**15618.37**	**−7947.362**

Bold shows smaller AIC and BIC.

unit increased in age, the average IOP of the patients was significantly increased by 0.0726 mmHg (P-value < .0001). The average IOP of the patient who lived urban was significantly lower by 1.8443 mmHg (P-value = .0005) compared to the patient who lived in the rural area.

The average IOP of the patient who had hypertension was significantly higher by 4.5076 mmHg (P-value < .0001) compared to the patient who had no hypertension. The average IOP of the patient who take pilocarpine medication were significantly lower by 3.3413 mmHg (P-value = .0041) compared to the patient who take timolol medication and the average IOP of the patient who take timolol with Diamox medication were significantly higher by 2.3838 mmHg (P-value = .0051) compared to the patient who take timolol medication. The average IOP of the patient who had greater than 0.7 cup-disk ratio was significantly higher by 2.9238 mmHg (P-value < .0001) compared to the patient who had less than or equal to 0.7 cup-disk ratio. For a unit increased in the visits (follow-up time), the average IOP of glaucoma patients was significantly decreased by 0.3489 mmHg (P-value < .0001) keeping all other variables constant.

In the survival sub model, for a unit increased in age, the hazard of blindness of glaucoma patients was significantly increased by 2% (P-value = .0020). The risk of blindness of the glaucoma patient who had hypertension was 2.129

Table 6. Result of the final linear mixed model for glaucoma patients.

COVARIATES	ESTIMATE	SE	95% CI		P-VALUE
			LOWER	UPPER	
Intercept	25.1829	1.3011	22.6374	27.7286	<.0001*
Age	0.0662	0.0216	0.0260	0.1064	.0013*
Residence(ref = rural)					
Urban	−1.5994	0.6317	−2.8353	−0.3634	.0114*
Hypertension (ref = no)					
Yes	4.9043	0.7799	3.3785	6.4301	<.0001*
Type of medication (ref = timolol)					
Timolol and Pilocarpine	−2.0206	1.0164	−4.0127	−0.0285	.0468*
Timolol and Diamox	−0.0253	1.0976	−2.1766	2.1259	.9816
Timolol, Pilocarpine, and Diamox	0.8961	1.2050	−1.4656	3.2579	.1085
Cup-disk ratio (ref = ⩽ 0.7)					
Greater than 0.7	2.6025	0.6924	1.2437	3.9614	.0002*
Visits	−0.3377	0.0659	−0.4666	−0.2088	<.0001*
RANDOM EFFECT	SD	95% CI			
		LOWER	UPPER		
Intercept (b_{0i})	5.5785	4.7898	6.4970		
Visits (b_{1i})	0.4951	0.3234	0.7580		
Corr (b_{0i}, b_{1i})	−0.5709	−0.7496	−0.3148		
Residual (ε_i)	6.5360	6.2929	6.7884		

Abbreviation: Ref, reference category.
*Shows significant at .05 level of significance.

(P-value = .0042) times the risk of blindness of the patient who had no hypertension. The risk of blindness of the glaucoma patient who had diabetic disease was 1.564 (P-value = .0478) times the risk of blindness of the patient who had no diabetic disease. The risk of blindness of the glaucoma patient who took pilocarpine medication was 0.645 (P-value = .0110) times the risk of blindness of the patient who took timolol medication. The risk of blindness of the glaucoma patient who had medium duration of treatment and long duration of treatment were 0.036 (P-value < .0001) and 0.0014 (P-value < .0001) times the risk of blindness of the patient who had short duration of treatment respectively keeping all other variables constant. The risk of blindness of the glaucoma patient who had greater than 0.7 cup-disk ratio was 3.732 (P-value < .0001) times the risk of blindness of the patient who had less than or equal to 0.7 cup-disk ratio keeping all other variables constant. The estimate of the association parameter was $\alpha = .0160$ (P-value = .0349),

indicating that there is a positive association between IOP and time to blindness of glaucoma patients. The result indicates that the higher value of IOP was associated with the higher risk of blindness (Table 8).

Comparison of separate and joint model

The estimates of the parameters of the separate and joint models are quite similar to each other but not identical. To compare separate and joint models based on standard error computed in the 2 models for significant predictors. The model with smaller standard error is the better fit for the data. When evaluating the overall performance of both the separate and joint models in terms of model parsimony and goodness of fit, the joint model was performed better based on its lower AIC, BIC and based on a significant likelihood ratio test as well. The association parameter being significant was also evidence that the

Table 7. Result of the final Cox proportional hazards model for glaucoma patients.

COVARIATES	ESTIMATE	SE	HR (95% CI)	*P*-VALUE
Age	0.0177	0.0084	1.0179 (1.0013, 1.0347)	.0344*
Blood pressure (ref=no)				
Yes	1.0341	0.2666	2.8127 (1.6681, 4.7426)	<.0001*
Diabetic disease (ref=no)				
Yes	0.4672	0.2322	1.5954 (1.0121, 2.5149)	.0442*
Type of medication (ref=timolol)				
Timolol and Pilocarpine	-0.5902	0.2988	0.5542 (0.3086, 0.9955)	.0483 *
Timolol and Diamox	-0.3549	0.2698	0.7012 (0.4133, 1.1898)	.1883
Timolol, Pilocarpine, and Diamox	-0.0805	0.2865	0.9227 (0.5262, 1.6179)	.2241
Duration of treatment (ref.=short)				
Medium	-3.7940	0.5370	0.0225 (0.0079, 0.0645)	<.0001*
Long	-7.7605	1.1528	0.0004 (0.00004, 0.0041)	<.0001*
Cup-disk ratio (ref. ≤ 0.7)				
Greater than 0.7	1.3079	0.3208	3.6985 (1.9724, 6.9354)	<.0001*

Abbreviation: Ref, reference category.
*Shows significant at .05 level of significance.

joint model was better fit than the separate models in this study. The residual variability was smaller in joint model analysis as compared to separate model analysis which indicates that the standard errors were adjusted for the correlation between the 2 responses in the joint model.

Discussion

In this study, 3 different models were explored, the linear mixed effects model for longitudinal IOP, Cox proportional hazards model for survival time of glaucoma patients independently, and jointly modeling of the 2 outcomes together.

In this study, the association parameter was statistically significant in the joint model, indicates that the 2 responses were correlated and shows that the joint model is better fit to the data than the separate models. This finding was consistent with another study.[19]

Age is an important socio-demographic predictor of IOP and time to blindness implies that the average IOP and risk of blindness increases with increase in age. This result was in line with other studies,[20,21] the result shows that higher age was a significant risk factor for blindness of glaucoma patients. This might be older people who live with ocular hypertension due to this reason increase IOP in older age.

The average IOP was found evolving differently between patients who had hypertension and patients who had no hypertension based on the result of separate and joint models. The average IOP is higher for patients who had hypertension compared to patients who had no hypertension. This result was consistent with other studies.[8,22]

The glaucoma patients treated with a combination of different medications are exposed to increase of IOP and this further leads to blindness as compared to patients treated with only 1 type of medication. The potential reason for this might be the interaction effect of different medication and management problems of such combined treatment by patients. This finding was consistent with another study,[23] the result showed that the use of a single class of glaucoma medication as simple to manage to reduced hazard of blindness and this is due to lack of knowledge by patients about glaucoma disease to take the medication and patients might be careless for managing combine medication due to the disease nature (the disease most of the time is painless). However, the result obtained in the current investigation contradicts with another study.[23] This contradiction might be the difference of knowledge, attitude, and practice of glaucoma patients who took the medication.

The risk of blindness of patients who had a cup-disk ratio greater than 0.7 is higher compared to patients who had a cup-disk ratio less than or equal to 0.7. This finding was consistent with another study,[24] the result showed that increased the incidence of blindness in a larger cup-disc ratio >0.7. The result associated with cup disc-ratio with size of IOP and hardness of being blindness is consistent with previous studies.[9,25] The

Table 8. Result of joint model of longitudinal IOP and time to blindness of glaucoma patients.

LONGITUDINAL PROCESS				SURVIVAL PROCESS			
PARAMETER	β	SE (β)	P-VALUE	PARAMETER	β	SE (β)	P-VALUE
Intercept	25.1515	1.0830	<.0001	Age	0.0197	0.0064	.0020
Age	0.0726	0.0171	<.0001	Blood pressure (yes)	0.7556	0.2640	.0042
Residence (urban)	-1.8443	0.5297	.0005				
Blood pressure (yes)	4.5076	0.6420	<.0001	Diabetic disease (yes)	0.4474	0.2261	.0478
Type of medication (ref=timolol)				Type of medication (ref=timolol)			
Pilocarpine	-3.3413	1.1630	.0041	Pilocarpine	-0.4392	0.1727	.0110
Diamox	-0.3172	0.9219	.7308	Diamox	-0.1953	0.4324	.6516
Timolol and pilocarpine	-0.5245	0.8649	.5442	Timolol and pilocarpine	0.0021	0.3233	.9947
Timolol and diamox	2.3838	0.8509	.0051	Timolol and diamox	0.2209	0.2845	.4374
Timolol, pilocarpine, and diamox	1.1172	0.8156	.1707	Timolol, pilocarpine, and diamox	0.3131	0.2939	.2867
Cup-disk ratio (ref ≤ 0.7)				Duration of treatment (ref=short)			
Greater than 0.7	2.9238	0.5744	<.0001				
Visits	-0.3489	0.0549	<.0001	Medium	-3.3290	0.2185	<.0001
				Long	-6.5859	0.3187	<.0001
RANDOM EFFECT	SD			CUP-DISK RATIO (REF ≤ 0.7)			
Intercept (b_{0i})	5.4965			>0.7	1.3170	0.3331	<.0001
Visits (b_{1i})	0.2049			Assoct (α)	0.0160	0.0076	.0349
Corr (b_{0i}, b_{1i})	-0.7788						
Residual (ε_i)	6.5024						

Abbreviation: Ref, reference category.
*Shows significant at .05 level of significance.

probable explanation is when a cup-disk ratio increased, IOP also increased due to the nature of the disease.

The result shows the significance of the shared parameter that links the 2 processes together in a joint model while also taking into account the association between them and the reduction in the standard error of the parameter estimates and more efficient inferences when compared to separate model estimates. Therefore, the joint model analysis fits the data better compared to the separate models in current investigation. However, the betterment of the joint model in current investigation may not be true in any other studies because of the nature of data collected from the field.

Conclusion

A joint model and the corresponding separate sub models were built using a retrospective data obtained from an ophthalmology clinic of glaucoma patients under the follow-up 2014 to 2018 at Felege Hiwot Referral Hospital, Bahir Dar, Ethiopia. This study addressed the relationship between the repeated measures IOP and time to blindness of glaucoma patients using joint modeling with a linear mixed effects sub model and a Cox proportional hazards survival sub model.

In conclusion, the results of both separate and joint analyses were quite similar but not identical. However, the use of a joint model analysis compared to separate model analysis adjusted for the correlation between the 2 responses indicates that reducing the standard error and efficient inferences can be made using joint model estimates. In the current investigation the predictors; age, blood pressure, type of medication, cup-disk ratio, and visits were jointly and significantly associated with the 2 response variables namely the change of IOP and time to blindness.

The way forward: The health staff should conduct health related education for individuals to examine or a continuous check-up of their eye based on their age. Health professionals, government, and non-governmental organizations give more attention to minimize the risk of blindness of glaucoma patients by reducing patient intraocular pressure during the follow-up time and create awareness for patients about irreversible blindness caused by glaucoma disease. Health professionals give more attention to types of medication to reduce progression of glaucoma when the patients come back again in the hospital. Health professionals give more attention to patients who have hypertension and patients who have a cup-disk ratio greater than 0.7 during the follow-up time to reduce intraocular pressure and to minimize the risk of blindness of glaucoma patients.

Ethics Consideration

The authors got an ethical approval certificate from Bahir Dar University Ethical approval committee, Bahir Dar, Ethiopia with Ref≠BDU/55/2018 to use the secondary data related to patients. The Ethical approval certificate obtained in this committee can be attached up on request. Since the data used in the current investigation was secondary, there was no verbal or written consent from the participants.

ORCID iD

Mitiku Wale Muluneh ![ORCID] https://orcid.org/0000-0002-2413-8026

Availability of Data and Materials

Data are available on reasonable request.

REFERENCES

1. Davis BM, Crawley L, Pahlitzsch M, Javaid F, Cordeiro MF. Glaucoma: the retina and beyond. *Acta Neuropathol*. 2016;132:807-826.
2. Durowade KA, Salaudeen AG, Akande TM, et al. Prevalence and risk factors of glaucoma among adults in rural and urban communities of Ilorin West Local Government Area, North-Central Nigeria. *Int J Clin Med Res*. 2016;3: 6-12.
3. Farandos NM, Yetisen AK, Monteiro MJ, Lowe CR, Yun SH. Contact lens sensors in ocular diagnostics. *Adv Healthc Mater*. 2015;4:792-810.
4. Shafiq I. Influence of central corneal thickness (CCT) on intraocular pressure (IOP) measured with goldmann applanation tonometer (GAT) in normal individuals. *Pak J Ophthalmol*. 2008;24(4):196-200.
5. Bhargava JS, Patel B, Foss AJ, Avery AJ, King AJ. Views of glaucoma patients on aspects of their treatment: an assessment of patient preference by conjoint analysis. *Invest Ophthalmol Vis Sci*. 2006;47:2885-2888.
6. Janz NK, Wren PA, Guire KE, et al. Fear of blindness in the Collaborative Initial Glaucoma Treatment Study: patterns and correlates over time. *Ophthalmology*. 2007;114:2213-2220.
7. Seol BR, Kim S, Kim DM, Park KH, Jeoung JW, Kim SH. Influence of intraocular pressure reduction on progression of normal-tension glaucoma with myopic tilted disc and associated risk factors. *Jpn J Ophthalmol*. 2017;61:230-236.
8. Zhao D, Kim MH, Pastor-Barriuso R, et al. A longitudinal study of association between adiposity markers and intraocular pressure: the Kangbuk Samsung Health Study. *PLoS One*. 2016;11:e0146057.
9. Guo X, Carlin BP. Separate and joint modeling of longitudinal and event time data using standard computer packages. *Am Stat*. 2004;58:16-24.
10. Faucett CL, Thomas DC. Simultaneously modelling censored survival data and repeatedly measured covariates: a Gibbs sampling approach. *Stat Med*. 1996;15:1663-1685.
11. Lavalley MP, Degruttola V. Models for empirical Bayes estimators of longitudinal CD4 counts. *Stat Med*. 1996;15:2289-2305.
12. Tsiatis A, Degruttola V, Wulfsohn M. Modeling the relationship of survival to longitudinal data measured with error. Applications to survival and CD4 counts in patients with AIDS. *J Am Stat Assoc*. 1995;90:27-37.

13. Wulfsohn MS, Tsiatis AA. A joint model for survival and longitudinal data measured with error. *Biometrics*. 1997;53:330-339.
14. Wu L, Liu W, Yi GY, Huang Y. Analysis of longitudinal and survival data: joint modeling, inference methods, and issues. *J Probab Stat*. 2012;2012:17.
15. Melka F, Alemu B. The pattern of glaucoma in Menelik II Hospital Addis Ababa, Ethiopia. *Ethiop Med J*. 2006;44:159-165.
16. West BT, Welch KB, Galecki AT. *Linear Mixed Models: A Practical Guide Using Statistical Software*. Chapman and Hall/CRC; 2014.
17. Ibrahim JG, Chu H, Chen LM. Basic concepts and methods for joint models of longitudinal and survival data. *J Clin Oncol*. 2010;28:2796.
18. Rizopoulos D. *Joint Models for Longitudinal and Time-to-Event Data: With Applications in R*. Chapman and Hall/CRC; 2012.
19. Seid A, Getie M, Birlie B, Getachew Y. Joint modeling of longitudinal CD4 cell counts and time-to-default from HAART treatment: a comparison of separate and joint models. *Electron J Appl Stat Anal*. 2014;7:292-314.
20. Rossetti L, Digiuni M, Giovanni M, et al. Blindness and glaucoma: a multicenter data review from 7 academic eye clinics. *PLoS One*. 2015;10: e0136632.
21. Tamrat L, Gessesse GW, Gelaw Y. Adherence to topical glaucoma medications in Ethiopian patients. *Middle East Afr J Ophthalmol*. 2015;22:59.
22. Han X, Yang T, Zhang J, et al. Longitudinal changes in intraocular pressure and association with systemic factors and refractive error: Lingtou Eye Cohort Study. *BMJ Open*. 2018;8:e019416.
23. French DD, Margo CE. Glaucoma medications and mortality: a retrospective cohort study. *Ann Epidemiol*. 2010;20:917-923.
24. Gardiner SK, Johnson CA, Demirel S. Factors predicting the rate of functional progression in early and suspected glaucoma. *Invest Ophthalmol Vis Sci*. 2012;53:3598-3604.
25. Lim HJ, Mondal P, Skinner S. Joint modeling of longitudinal and event time data: application to HIV study. *J Med Stat Inform*. 2013;1:1.